Upfront Briefing
Health Canada handed Sobi a new label win for EMPAVELI in rare kidney disease, while dealmaking stayed active across next-wave oncology modalities: Roche struck a new degrader-antibody conjugate pact with C4 Therapeutics, and AbbVie kept channel economics in focus by pressing a new 340B “patient” definition in litigation.
On the capital calendar, Oricell closed a $110M pre-IPO financing to push solid tumor CAR-T, and BioCentury floated an “America First PDUFA” concept that would tie fee incentives to domestic first-in-human trials.
Tape Action
| Instrument |
Last close |
1D % |
YTD % |
| S&P 500 |
6,824.7 |
+0.6% |
(0.3%) |
| Nasdaq 100 |
25,082.1 |
+0.7% |
(1.2%) |
| Russell 2000 |
2,636.3 |
+0.6% |
+6.2% |
| Healthcare (XLV) |
149.3 |
(0.2%) |
(4.7%) |
| Biotech (XBI) |
131.8 |
+0.9% |
+5.9% |
| Nasdaq Biotech (NBI) |
5,945.9 |
+0.4% |
+2.2% |
| Clinical Trials (BBC) |
44.5 |
+2.4% |
+12.4% |
|
- Relief on the macro tape drove Thursday’s move: U.S. equities extended their rebound as diplomatic de-escalation in the Middle East eased the market’s immediate oil, inflation and growth scare.
- Biotech beta outperformed defensives once that pressure lifted: XBI +0.9% versus XLV (0.2%), suggesting investors rotated back into higher-risk healthcare rather than hiding in large-cap defensives.
- Standout mover: Clinical Trials (BBC) jumped +2.4%, the best move on the tape, reinforcing that development-stage exposure can re-rate quickly when macro headwinds stop intensifying.
- Market data: U.S. close Thu 09-Apr-2026.
The Big 3
|
1
|
Health Canada approves Sobi's EMPAVELI for C3G, IC-MPGN
|
- Sobi said Health Canada approved EMPAVELI (pegcetacoplan) for the treatment of C3G and primary IC-MPGN, expanding labeled use in rare kidney disease.
- Why it matters: This is useful mainly as a commercial readthrough. EMPAVELI already had proof the market cared about complement biology; the question now is whether Sobi can turn incremental renal labels into real uptake, reimbursement depth and longer-duration franchise value in rare nephrology.
- Source: PR
- More: PR
|
|
2
|
Roche pays $20M upfront for C4 degrader-antibody conjugate pact
|
- Roche agreed to pay C4 Therapeutics $20 million upfront and commit more than $1 billion in milestones across two oncology degrader-antibody conjugate targets, with an option to add a third.
- Why it matters: The important part here is not the $20M upfront by itself; it is what Roche is choosing to pay for. Large-cap pharma is still writing checks for differentiated oncology delivery formats before there is full clinical proof, which is a positive signal for degrader-enabled platforms and for the view that the next ADC wave will be built around better biology, not just more payloads.
-
Source:
Fierce Biotech
|
|
3
|
Oricell closes $110M pre-IPO financing for solid tumor CAR-T
|
-
Oricell Therapeutics said it closed a pre-IPO financing round in excess of $110 million. The round was co-led by Vivo Capital, Beijing Medical and Health Care Industry Investment Fund, Qiming Venture Partners, and an unnamed global healthcare fund, with participation from an international sovereign wealth fund, E-Town Capital, Luxin Venture Capital, NGS Super, Elikon Investment, and Talon Capital.
-
Why it matters: Solid-tumor CAR-T still sits in the prove-it bucket, so a round of this size matters less as a financing headline than as a confidence signal. Investors will read it as a bet that Ori-C101 is mature enough to justify late-pre-pivotal capital and that the crossover market is still open to cell therapy stories with a plausible path beyond early proof-of-concept.
-
Source:
PR
|
Everything Else that broke
- BioCentury outlines an America First PDUFA approach that shifts from punitive measures to reward-based fee incentives tied to domestic first-in-human trials. — BioCentury
- Invivyd revealed plans to test an antibody drug against measles, opening a new development angle beyond its Covid-era narrative. — BioPharma Dive
- Researchers reported one CAR-T cell therapy drove three autoimmune diseases into remission at once, adding to the emerging clinical case that cell therapy may have broader utility in severe autoimmunity than single-indication development frames imply. — Fierce Biotech
- Innovent Biologics reported preclinical data for IBI3055, a tri-specific T cell engager aimed at autoimmune disease, underscoring how aggressively the China biotech cohort is pushing TCE logic beyond oncology. — PR
- Endpoints reported FDA lifted a MacroGenics hold and also flagged a new Oxford Science Enterprises / Bristol Myers Squibb tie-up. — Endpoints
Deal Flow
| BioBucks 2026 Deal Trackers • Updated weekly ⬇️
|
M&A / BD&L
- Junction said it is collaborating with GRAIL to power scalable access to the Galleri multi-cancer early detection test. — PR
- Gilead exercised its option on Kymera’s preclinical CDK2 molecular glue degrader KT-200, triggering a $45M payment and setting up up to $665M in remaining milestones. — Fierce Biotech
VC / Private Financings
- Oricell Therapeutics said it closed a pre-IPO financing round in excess of $110 million. The syndicate was co-led by Vivo Capital, Beijing Medical and Health Care Industry Investment Fund, Qiming Venture Partners, and an unnamed global healthcare fund, with participation from an international sovereign wealth fund, E-Town Capital, Luxin Venture Capital, NGS Super, Elikon Investment, and Talon Capital. — PR
IPOs / Follow-Ons
- No major new biotech IPO or follow-on announcements of note crossed after Thursday’s cutoff; Avalyn’s filing was already covered in Thursday’s edition.
Things that make you go hmmm ...
Most known diseases are ultra-rare and neglected by the pharma industry. Source: Nature Biotechnology
Academic Corner
- Assessing Colorectal Cancer and Mortality Risk in Older Adults. — JAMA
- Prevention of Respiratory Syncytial Virus–Related Hospitalization in Newborns. — JAMA
- Colorectal Cancer and Mortality Risk Among Older Adults With vs Without Adenoma on Prior Colonoscopy. — JAMA
|
